esmo

ESMO 2021 Transgene presents data confirming the potential of oncolytic virus TG6002 administered intravenously Donwload Press release (PDF) TG6002 en images

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00

 

© 2021 Transgene - All rights reserved
Terms of use - Credits